Response to second line chemotherapy in ovarian cancer of epithelial origin.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004848:Epithelium; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies
D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic